Item 2.01 Completion of Acquisition or Disposition of Assets.
As previously disclosed in the Current Report on Form 8-K filed by Tandem
Diabetes Care, Inc., a Delaware corporation (the "Company"), with the Securities
and Exchange Commission (the "SEC") on December 13, 2022, the Company entered
into a Share Purchase Agreement, dated as of December 10, 2022 (the "Purchase
Agreement"), by and among the Company, the Sellers listed on Annex B of the
Purchase Agreement (collectively, the "Sellers" and each, individually, a
"Seller") and AMF Medical SA, a corporation organized and existing under the
laws of Switzerland ("AMF Medical").
On January 19, 2023, the Company completed the acquisition of AMF Medical,
pursuant to the terms of the Purchase Agreement. The total aggregate
consideration for the transaction includes a previous strategic investment of
Swiss Francs ("CHF") 8.0 million paid in the third quarter of 2022, a cash
payment of CHF 62.4 million paid at the closing of the transaction, and
additional contingent earnout payments, further described in the Purchase
Agreement and in the Company's Current Report on Form 8-K with the SEC on
December 13, 2022.
The foregoing description of the Purchase Agreement and the transaction does not
purport to be complete and is qualified in its entirety by reference to the full
text of the Purchase Agreement, which will be filed as an exhibit to the
Company's Annual Report on Form 10-K for the year ending December 31, 2022.
The Company issued a press release announcing the completion of the acquisition
of AMF Medical on January 23, 2023, a copy of which is attached hereto as
Exhibit 99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Number Description
99.1 Press release of Tandem Diabetes Care, Inc. dated January 23, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses